Alloy Therapeutics Raises $40M Series E at $1B Valuation, Advances 22 AI-Driven Therapies into Clinical Trials with Support from Pfizer and Sanofi
Alloy Therapeutics
Drug Discovery and Development Service Provider
AI Pharmaceutical Welcomes AgainHeavyweightFinancing！
Recently, Alloy Therapeutics, Inc., an AI pharmaceutical company based in Boston, U.S.Alloy Therapeutics AnnouncementCompleted$40 millionSeries E financing.
After this round of financing, the company's latest round of financing valuation is$1 billion。
This Round's Participating InvestorsIncluding8VC、JIC Venture Growth Investments、Echo Capitaland many other well-known institutions. Notably,Peter ThielUnder its umbrellaThiel Capital、Founders Fund, andMubadala Capital、Alexandria Venture InvestmentsExisting shareholders, including Alloy Therapeutics, Inc., have all chosen to follow up on their investments.
This round of funding will be mainly used for:
RiseLevelAI/ML Drug Discovery EngineWith the data layer，Strengthen AI and machine learning capabilities, and build data infrastructure that connects the entire development process.
Deepening Antibodies, Gene Medicines, and Cell TherapiesCore Platform
Expand Preclinical& Clinical Development ServicesWu NengForce
AlloyFounded in2017Year, FoundingPersonErrik AndersonWith many years of experience in the biotechnology industry, having participated in several successful startups, including Adimab, LLC, Arsanis, and Alloy Therapeutics.
The company initially focused on antibody discovery but later expanded to coverBispecific antibodies, gene drugs, cell therapies, and other fields.
Now, by integrating AI-driven models, wet labs, and real-world data, Alloy Therapeutics is positioning itself as a comprehensive service platform capable of accelerating progress and reducing costs.
The founder stated that the company is committed to becoming the infrastructure for pharmaceutical research and development.
“Alloy is building the infrastructure layer that connects discovery, development, and data across the global biopharmaceutical industry.。"Our collaboration model allows partners to stay at the forefront without having to build all capabilities in-house."
As of now,AlloyHas been in cooperation with200Multiple PartnersEstablish cooperation. These cooperations have generatedExceed100A licensed treatment program. Among them22Have entered the clinical development stage,2An individual in3Phase Clinical.
In recent years,Alloy Therapeutics Multiple Significant BD Deals Successfully Completed, Partnerships EstablishedIncludingSanofi, Pfizer,BiogenSuch multinational pharmaceutical giants as.
April 6, the company and BiogenAchieve MoreTarget Collaboration, ASO-BasedThe platform develops drugs for central nervous system diseases;
In February 2025, Alloy Therapeutics announced a strategic collaboration with Pfizer to jointly develop a novel platform for specific and effective antibodies;
January 2025, Alloy Therapeutics, Inc. andSanofiReach cooperation,Co-develop a novel antisense oligonucleotide (ASO) drugThe collaboration is worth $27.5 million, with milestone payments and royalties totaling $400 million.
This demonstrates that these collaborations highlight Alloy Therapeutics' cross-platform potential from antibodies, bispecific antibodies, to gene therapies and cell therapies.。
As pharmaceutical companies accelerate their layoutAI Pharmaceutical: Alloy Therapeutics' Global Expansion is Accelerating.
